Artery Network learned at the first opportunity that on December 15, Kyinno Biotechnology, a biotechnology company dedicated to the R&D of next-generation bispecific and multispecific antibody therapeutics, announced the successful completion of its Series B financing, raising nearly USD 35 million. It is reported that the proceeds from this round will primarily be used to accelerate co-development and clinical advancement of multiple First-in-Class (FIC) and Best-in-Class (BIC) bispecific/multispecific antibody programs, further strengthen the Company’s proprietary “common light chain” and “nanobody” technology platforms, and actively expand global business development (BD).
Kyinno Biotechnology, Inc. is a platform-driven biotechnology company specializing in next-generation bispecific and multispecific antibody technologies. Leveraging its proprietary common light chain and nanobody platforms, the Company provides integrated discovery and early-development capabilities to global partners, enabling and accelerating the development of First-in-Class and Best-in-Class antibody therapeutics. Kyinno’s technologies support programs across oncology, autoimmune diseases, and other therapeutic areas, empowering global pharmaceutical innovation through differentiated and scalable antibody platforms.
1. Deeply rooted in the dual/multi-resistance field, two underlying platforms form a core technological barrier.
As an innovation-driven biotech, Kyinno Biotechnology has focused on the drug discovery stage since its establishment in 2017. The Company has built the industry’s largest gene-edited cell libraries, common light chain mice, nanobody platforms, and related validation systems. Through breakthroughs in antibody discovery technologies, it has addressed key industry pain points in traditional bispecific antibody development, including low discovery efficiency, heavy and light chain mispairing, poor developability, and complex manufacturing processes. The combined application of the common light chain and nanobody platforms has also significantly expanded the Company’s combinatorial space and design capability in multispecific antibodies.
The success of this financing round stems from investors’ strong recognition of the value of Kyinno Biotechnology’s two core technology platforms:
One of the major challenges in bispecific antibody development is screening efficiency. Based on AI and bioinformatics technologies, the Company has designed patented light chain sequences that greatly improve compatibility with heavy chains, ensuring the identification of bispecific molecules that meet target-specific characteristics. Another key challenge is heavy and light chain mispairing. Through its common light chain technology, Kyinno Biotechnology eliminates light chain mispairing at the source, significantly simplifying CMC (Chemistry, Manufacturing, and Controls) process development. AI-assisted design substantially improves assembly efficiency and stability of bispecific molecules, laying a solid foundation for developing highly developable FIC bispecific/multispecific antibodies.
By utilizing genetically engineered mouse platforms, the Company can efficiently screen nanobodies with unique epitope-binding capabilities and excellent tissue penetration. Combined with its mature alpaca-based nanobody development technology, this ensures a high success rate in nanobody discovery against target antigens. This platform complements the common light chain mouse antibody technology, particularly demonstrating highly competitive differentiation advantages in constructing multispecific antibodies for complex targets or enhancing efficacy through multivalent design.
2. Focusing on early drug discovery, we will build multiple validation platforms to empower global pharmaceutical R&D.
From gene-edited cell model construction to antibody discovery and AI-assisted design, and further to in vivo and in vitro efficacy evaluation, the Company has established a one-stop technology platform covering key stages of early drug discovery, enabling enterprises to more agilely capture R&D trends. At the same time, it promotes mutual growth by establishing deep and flexible strategic partnerships with clients.
